in the spotlight: oncology

At present, cytotoxic drugs dominate in the treatment of cancer despite the problems associated with these agents. With the emergence of new technologies we are well positioned, along with our partners, to offer a growing range of tailored treatment options for different types of cancer. Innovative approaches for selection of products for further development is the key in our drive to improve the outcome of treatment for patients.

Bendamustine is used in the treatment of Non Hodgkin Lymphoma, Multiple Myeloma and Chronic Lymphatic Leukemia. We continue to develop Bendamustine further in collaboration with our partners.

Pralatrexate injection is a folate analogue metabolic inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma in the US and currently has an marketing authorization application filed with the EMA for the same indication. We are working with our partners to develop Pralatrexate in a number of other hematologic malignancies.

Forodesine is a rationally designed, potent, transition-state, analog inhibitor of purine nucleoside phosphorylase (PNP). Data obtained to date makes us optimistic that forodesine could be active in several haematological cancers.

IPI-926 is a novel, proprietary inhibitor of the Hedgehog signalling pathway. Abnormal activation of the Hedgehog pathway can lead to cancer and is believed to play a central role in allowing the proliferation and survival of several types of cancers, including pancreatic, prostate, lung, breast, and certain brain cancers advanced solid tumours.
In all, we are very excited about our future in the field of oncology!

 

print page